Hypertension associated with primary aldosteronism
Conditions
Interventions
Experimental group:Adrenal chemical ablation was performed in the experimental group
Sponsors
Meishan People's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: ? Patients with hypertension of grade 2 or above or refractory hypertension; ? Hypertension combined with hypokalemia; ? Young and middle-aged hypertensive patients with early onset (<40 years old) cerebrovascular accident ? Hypertensive patients with close relatives of PA related hypertension; ? Age =18 years old; ? Subjects were willing to accept drug treatment and surgical treatment; ? Signing informed consent; Based on the international guidelines and clinical experience, the plasma aldosterone to renin activity ratio (ARR) test was performed in the suspected population of this project. When the unit of renin activity and aldosterone concentration were set as ng·ml-1·h-1 and ng/dl, respectively, the ARR cut-off point was set greater than 20 for initial screening positive. The clinical confirmatory test in this study was the saline infusion test (SIT), and the result was defined as a blood aldosterone level greater than 10ng/dl.
Exclusion criteria
Exclusion criteria: ? Inability to complete the assessment due to non-cardiovascular diseases such as dementia and disability; ? Patients unwilling to participate in the study; ? Patients with a life expectancy of less than 6 months due to advanced disease; ? Patients with angina pectoris in daily activities or resting state; ? New York Heart Association (NYHA) class ? or above; ? Patients with puncture site infection; ? Aortic dissection; ? Patients with coagulation dysfunction; ? Symptomatic or severe aortic stenosis, mitral stenosis, or hypertrophic obstructive cardiomyopathy; ? Malignant arrhythmia, high degree atrioventricular block. ? known skin allergy to adhesives (hydrocolloids, silicone, acrylic); ? Hypertension associated with other causes (pheochromocytoma, primary hypercortisolism, renal artery stenosis, etc.) has been identified
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Blood pressure;Cardiac function; | — |
Secondary
| Measure | Time frame |
|---|---|
| BNP;renal function;Serum aldosterone levels; | — |
Countries
China
Contacts
Public ContactDing Huai Sheng
Meishan People's Hospital
Outcome results
None listed